• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Durable, safe and ef­fec­tive long-term kid­ney drug da­ta from Tri­ci­da fu­el block­buster po­ten­tial

7 years ago
R&D

Gilead scores a TKO with PhI­II fil­go­tinib da­ta, but still faces some big bouts — and doubts — ahead

7 years ago
R&D

Amarin takes ap­pli­ca­tion to ex­pand Vas­cepa la­bel to the FDA as M&A chat­ter heats up

7 years ago
Pharma

As­traZeneca CEO So­ri­ot bets up to $7B on a ma­jor league col­lab­o­ra­tion for a game-chang­ing HER2 can­cer drug

7 years ago
Deals

Got­tlieb seeks new com­par­a­tive ap­proval stan­dard for opi­oids

7 years ago
Pharma

First Ab­b­Vie chopped a PhI­II, then they wrote off $4B in book val­ue. Now 178 Stem­cen­trx work­ers are get­ting the ax

7 years ago
R&D

Three biotechs raise $100M+ in fund­ing for gene ther­a­pies, can­cer vac­cines and more

7 years ago
News Briefing

Months af­ter Imfinzi com­bo flops, As­traZeneca wins NICE en­dorse­ment as lung can­cer monother­a­py

7 years ago
Pharma

Lit­tle Pro­teon shares crash in­to pen­ny stock ter­ri­to­ry as lead drug flops in PhI­II

7 years ago
R&D

Sure Hervé Hop­penot took a big cut in com­pen­sa­tion af­ter a pipeline dis­as­ter. But he still outscored the on­ly woman ...

7 years ago
People

Il­lic­it drugs are mak­ing some big ad­vances in R&D, and Thiel part­ners at ATAI get a $43M bankroll to fu­el dri­ve on ...

7 years ago
Financing

Pre­ci­sion Bio wants to show there's a bet­ter way to ed­it genes — and now it has $126M in IPO cash to prove it

7 years ago
Financing

We de­stroyed near­ly 8,000 packs of ex­pired Orkam­bi stock last year, Ver­tex tells UK MPs

7 years ago
Pharma

Af­ter a 33-year odyssey, Jef­frey Blue­stone grabs a ring­side seat to watch his drug teplizum­ab go back in­to the clin­ic

7 years ago
People

Promis­ing to match more NSCLC pa­tient with tar­get­ed drugs, Cam­bridge spin­out Ini­va­ta read­ies US launch of liq­uid ...

7 years ago
Financing

Key blad­der can­cer da­ta pave way for Seat­tle Ge­net­ics to sub­mit mar­ket­ing ap­pli­ca­tion for armed an­ti­body

7 years ago
R&D

As AI per­me­ates clin­i­cal an­a­lyt­ics, Per­cep­tive Ad­vi­sors bets $40M in­to a sto­ried play­er in the field

7 years ago
Financing
AI

Jim Mel­lon's Ju­ve­nes­cence takes a chance on tiny up­start run by for­mer Pfiz­er ex­ec

7 years ago
People
Financing

Louisiana sub­scribes to Gilead­'s Net­flix-style plan for hep C; Ono is in­vest­ing mil­lions in a new I/O re­search ...

7 years ago
News Briefing

Pain free? Meet Cas­sa­va, the newest Alzheimer’s play­er on Nas­daq

7 years ago
R&D

FDA’s On­col­o­gy Cen­ter of Ex­cel­lence touts 2018 ac­com­plish­ments

7 years ago
Pharma

Ab­b­Vie gets its first ap­proval for a drug ex­ecs be­lieve could be worth up to $5B in an­nu­al sales

7 years ago
Pharma

Eight months af­ter fil­ing for IPO, the mak­er of Chi­na's Ebo­la vac­cine joins HKEX with $161M raise

7 years ago
R&D
China

Eli Lil­ly joins a troi­ka of Big Phar­mas that have tied up to a low-pro­file biotech with big as­pi­ra­tions in au­toim­mune ...

7 years ago
Pharma
First page Previous page 947948949950951952953 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.